ArticleMedicine2025
Exploring the causal relationship between Hashimoto thyroiditis and metabolic-associated fatty liver disease: A Mendelian randomization study.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the possible causal link between Hashimoto thyroiditis (HT), an autoimmune disorder, and metabolic-associated fatty liver disease (MAFLD), previously referred to as nonalcoholic fatty liver disease (NAFLD), a common metabolic condition. Using genome-wide association study data from large European populations, we performed a bidirectional Mendelian randomization (MR) analysis. We identified single nucleotide polymorphisms strongly associated with HT and MAFLD/NAFLD, which we used as instrumental variables to probe the causal relationship between these 2 conditions. The forward MR analysis, using the inverse variance weighted method, showed that HT may increase the risk of MAFLD/NAFLD (odds ratio = 1.065, 95% confidence intervals: 1.014-1.119, P = .011). However, the reverse MR analysis did not establish a significant causal effect of MAFLD/NAFLD on HT (P > .05). Sensitivity analyses were carried out to assess potential heterogeneity or pleiotropy, and the results supported the robustness of our findings, indicating no significant concerns. These results suggest that HT may be a risk factor for the development of MAFLD/NAFLD. The bidirectional MR study revealed an elevated risk of MAFLD/NAFLD in individuals with HT, but no causal relationship was found from MAFLD/NAFLD to HT in the opposite direction. This understanding could assist healthcare professionals in improving their comprehension and management of both HT and MAFLD/NAFLD, leading to more comprehensive clinical guidance for patients and promoting the development of interdisciplinary treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.